Hayato Tada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4003225/publications.pdf

Version: 2024-02-01

201674 168389 3,600 133 27 53 citations h-index g-index papers 133 133 133 5994 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Exome-wide association study of plasma lipids in >300,000 individuals. Nature Genetics, 2017, 49, 1758-1766.	21.4	470
2	Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nature Genetics, 2018, 50, 26-41.	21.4	286
3	Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history. European Heart Journal, 2016, 37, 561-567.	2.2	226
4	Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia. European Heart Journal, 2017, 38, 1573-1579.	2.2	132
5	Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan. Atherosclerosis, 2011, 214, 404-407.	0.8	99
6	Twelve–Single Nucleotide Polymorphism Genetic Risk Score Identifies Individuals at Increased Risk for Future Atrial Fibrillation and Stroke. Stroke, 2014, 45, 2856-2862.	2.0	95
7	Sitosterolemia, Hypercholesterolemia, and Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2018, 25, 783-789.	2.0	90
8	Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease. Journal of Clinical Lipidology, 2018, 12, 1436-1444.	1.5	81
9	Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation. Atherosclerosis, 2014, 236, 54-61.	0.8	78
10	Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. Circulation Research, 2017, 121, 81-88.	4.5	68
11	Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (<i>PCSK9</i>) Gain-of-Function Mutations. Circulation Journal, 2016, 80, 512-518.	1.6	67
12	The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis, 2010, 210, 166-172.	0.8	62
13	Assessment of Coronary Atherosclerosis in Patients With Familial Hypercholesterolemia by Coronary Computed Tomography Angiography. American Journal of Cardiology, 2015, 115, 724-729.	1.6	60
14	Rare Protein-Truncating Variants in <i>APOB</i> , Lower Low-Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002376.	3.6	57
15	Rare and Deleterious Mutations in ABCG5/ABCG8 Genes Contribute to Mimicking and Worsening of Familial Hypercholesterolemia Phenotype. Circulation Journal, 2019, 83, 1917-1924.	1.6	55
16	Homozygous Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2021, 28, 665-678.	2.0	55
17	Diagnosis and Management of Sitosterolemia 2021. Journal of Atherosclerosis and Thrombosis, 2021, 28, 791-801.	2.0	50
18	Infantile Cases of Sitosterolaemia with Novel Mutations in the ABCG5 Gene: Extreme Hypercholesterolaemia is Exacerbated by Breastfeeding. JIMD Reports, 2015, 21, 115-122.	1.5	45

#	Article	IF	CITATIONS
19	Exome Sequencing in Suspected Monogenic Dyslipidemias. Circulation: Cardiovascular Genetics, 2015, 8, 343-350.	5.1	45
20	Heterozygous <i> ABCG5 < /i > Gene Deficiency and Risk of Coronary Artery Disease. Circulation Genomic and Precision Medicine, 2020, 13, 417-423.</i>	3.6	45
21	Functional Characterization of Rare Variants Implicated in Susceptibility to Lone Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1095-1104.	4.8	44
22	A novel type of familial hypercholesterolemia: Double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene. Atherosclerosis, 2011, 219, 663-666.	0.8	43
23	Altered Metabolism of Low-Density Lipoprotein and Very-Low-Density Lipoprotein Remnant in Autosomal Recessive Hypercholesterolemia. Circulation: Cardiovascular Genetics, 2012, 5, 35-41.	5.1	40
24	Efficacy and Safety of Coadministration of Rosuvastatin, Ezetimibe, and Colestimide in Heterozygous Familial Hypercholesterolemia. American Journal of Cardiology, 2012, 109, 364-369.	1.6	35
25	Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. Journal of Atherosclerosis and Thrombosis, 2019, 26, 583-591.	2.0	34
26	Serum Triglycerides and Atherosclerotic Cardiovascular Disease: Insights from Clinical and Genetic Studies. Nutrients, 2018, 10, 1789.	4.1	32
27	Multiple Associated Variants Increase the Heritability Explained for Plasma Lipids and Coronary Artery Disease. Circulation: Cardiovascular Genetics, 2014, 7, 583-587.	5.1	29
28	Clinical characteristics of Japanese patients with severe hypertriglyceridemia. Journal of Clinical Lipidology, 2015, 9, 519-524.	1.5	29
29	Reference Intervals of Serum Non-Cholesterol Sterols by Gender in Healthy Japanese Individuals. Journal of Atherosclerosis and Thrombosis, 2020, 27, 409-417.	2.0	29
30	Assessments of Carotid Artery Plaque Burden in Patients With Familial Hypercholesterolemia. American Journal of Cardiology, 2017, 120, 1955-1960.	1.6	26
31	Machine learning-based risk model using 123I-metaiodobenzylguanidine to differentially predict modes of cardiac death in heart failure. Journal of Nuclear Cardiology, 2022, 29, 190-201.	2.1	25
32	Lipid Management in a Japanese Community: Attainment Rate of Target Set by the Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases 2012. Journal of Atherosclerosis and Thrombosis, 2017, 24, 338-345.	2.0	24
33	Effect of Cumulative Exposure to Low-Density Lipoprotein-Cholesterol on Cardiovascular Events in Patients With Familial Hypercholesterolemia. Circulation Journal, 2021, 85, 2073-2078.	1.6	24
34	Acute myocardial infarction in a 25-year-old woman with sitosterolemia. Journal of Clinical Lipidology, 2018, 12, 246-249.	1.5	23
35	Remnant lipoproteins and atherosclerotic cardiovascular disease. Clinica Chimica Acta, 2019, 490, 1-5.	1.1	23
36	Clinical Impact of Carotid Plaque Score rather than Carotid Intima-Media Thickness on Recurrence of Atherosclerotic Cardiovascular Disease Events. Journal of Atherosclerosis and Thrombosis, 2020, 27, 38-46.	2.0	23

#	Article	IF	Citations
37	Personalized medicine for cardiovascular diseases. Journal of Human Genetics, 2021, 66, 67-74.	2.3	23
38	Prognostic impact of cascade screening for familial hypercholesterolemia on cardiovascular events. Journal of Clinical Lipidology, 2021, 15, 358-365.	1.5	23
39	Autosomal Recessive Hypercholesterolemia: A Mild Phenotype of Familial Hypercholesterolemia: Insight from the Kinetic Study using Stable Isotope and Animal Studies. Journal of Atherosclerosis and Thrombosis, 2015, 22, 1-9.	2.0	22
40	Usefulness of Electrocardiographic Voltage to Determine Myocardial Fibrosis in Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2016, 117, 443-449.	1.6	22
41	A novel method for determining functional LDL receptor activity in familial hypercholesterolemia: Application of the CD3/CD28 assay in lymphocytes. Clinica Chimica Acta, 2009, 400, 42-47.	1.1	21
42	Clinical Perspectives of Genetic Analyses on Dyslipidemia and Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2017, 24, 452-461.	2.0	21
43	Serum triglycerides predict first cardiovascular events in diabetic patients with hypercholesterolemia and retinopathy. European Journal of Preventive Cardiology, 2018, 25, 1852-1860.	1.8	21
44	A Rare Coincidence of Sitosterolemia and Familial Mediterranean Fever Identified by Whole Exome Sequencing. Journal of Atherosclerosis and Thrombosis, 2016, 23, 884-890.	2.0	20
45	Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis. Atherosclerosis, 2017, 265, 225-230.	0.8	20
46	A catalog of the pathogenic mutations of LDL receptor gene in Japanese familial hypercholesterolemia. Journal of Clinical Lipidology, 2020, 14, 346-351.e9.	1.5	20
47	Achilles Tendon Thickness Assessed by X-ray Predicting a Pathogenic Mutation in Familial Hypercholesterolemia Gene. Journal of Atherosclerosis and Thrombosis, 2022, 29, 816-824.	2.0	20
48	Age-specific differences in prognostic significance of rhythm conversion from initial non-shockable to shockable rhythm and subsequent shock delivery in out-of-hospital cardiac arrest. Resuscitation, 2016, 108, 61-67.	3.0	19
49	First case of sitosterolemia caused by double heterozygous mutations in ABCG5 and ABCG8 genes. Journal of Clinical Lipidology, 2018, 12, 1164-1168.e4.	1.5	19
50	Universal Screening for Familial Hypercholesterolemia in Children in Kagawa, Japan. Journal of Atherosclerosis and Thrombosis, 2022, 29, 839-849.	2.0	19
51	Assessment of arterial stiffness in patients with familial hypercholesterolemia. Journal of Clinical Lipidology, 2018, 12, 397-402.e2.	1.5	18
52	Monogenic, polygenic, and oligogenic familial hypercholesterolemia. Current Opinion in Lipidology, 2019, 30, 300-306.	2.7	18
53	Duration of cardiopulmonary resuscitation in patients without prehospital return of spontaneous circulation after out-of-hospital cardiac arrest: Results from a severity stratification analysis. Resuscitation, 2018, 124, 69-75.	3.0	17
54	Amiodarone-induced reversible and irreversible hepatotoxicity: two case reports. Journal of Medical Case Reports, 2018, 12, 95.	0.8	17

#	Article	IF	CITATIONS
55	Postâ€prandial remnant lipoprotein metabolism in autosomal recessive hypercholesterolaemia. European Journal of Clinical Investigation, 2012, 42, 1094-1099.	3.4	16
56	Whole exome sequencing combined with integrated variant annotation prediction identifies asymptomatic Tangier disease with compound heterozygous mutations in ABCA1 gene. Atherosclerosis, 2015, 240, 324-329.	0.8	16
57	Molecular and functional characterization of familial chylomicronemia syndrome. Atherosclerosis, 2018, 269, 272-278.	0.8	16
58	Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene. Lipids in Health and Disease, 2020, 19, 3.	3.0	16
59	Familial Hypercholesterolemia: A Narrative Review on Diagnosis and Management Strategies for Children and Adolescents. Vascular Health and Risk Management, 2021, Volume 17, 59-67.	2.3	16
60	Common and Rare Variant Association Study for Plasma Lipids and Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2016, 23, 241-256.	2.0	15
61	Comprehensive genotyping in dyslipidemia: mendelian dyslipidemias caused by rare variants and Mendelian randomization studies using common variants. Journal of Human Genetics, 2017, 62, 453-458.	2.3	15
62	Remnant-like particles and coronary artery disease in familial hypercholesterolemia. Clinica Chimica Acta, 2018, 482, 120-123.	1.1	15
63	Aortic Root Calcification Score as an Independent Factor for Predicting Major Adverse Cardiac Events in Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2018, 25, 634-642.	2.0	15
64	Novel mutations of cholesteryl ester transfer protein (CETP) gene in Japanese hyperalphalipoproteinemic subjects. Clinica Chimica Acta, 2012, 413, 537-543.	1.1	14
65	Whole exome sequencing combined with integrated variant annotation prediction identifies a causative myosin essential light chain variant in hypertrophic cardiomyopathy. Journal of Cardiology, 2016, 67, 133-139.	1.9	14
66	Functional analysis of KCNH2 gene mutations of type 2 long QT syndrome in larval zebrafish using microscopy and electrocardiography. Heart and Vessels, 2019, 34, 159-166.	1.2	14
67	Low-Density Lipoprotein Cholesterol Level cannot be too Low: Considerations from Clinical Trials, Human Genetics, and Biology. Journal of Atherosclerosis and Thrombosis, 2020, 27, 489-498.	2.0	14
68	Lipoprotein Apheresis for Sitosterolemia. Annals of Internal Medicine, 2017, 167, 896.	3.9	13
69	Impact of genetic testing on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia (GenTLe-FH): a randomised waiting list controlled open-label study protocol. BMJ Open, 2018, 8, e023636.	1.9	13
70	Prominent Tendon Xanthomas and Abdominal Aortic Aneurysm Associated with Cerebrotendinous Xanthomatosis Identified Using Whole Exome Sequencing. Internal Medicine, 2018, 57, 1119-1122.	0.7	13
71	Extreme Contrast of Postprandial Remnant-Like Particles Formed in Abetalipoproteinemia and Homozygous Familial Hypobetalipoproteinemia. JIMD Reports, 2015, 22, 85-94.	1.5	12
72	Fasting and Non-Fasting Triglycerides and Risk of Cardiovascular Events in Diabetic Patients Under Statin Therapy. Circulation Journal, 2020, 84, 509-515.	1.6	12

#	Article	IF	Citations
73	Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: Result from a crossover study. Clinica Chimica Acta, 2011, 412, 1068-1075.	1.1	11
74	Genetic Variations, Triglycerides, and Atherosclerotic Disease. Journal of Atherosclerosis and Thrombosis, 2019, 26, 128-131.	2.0	11
75	Impact of functional studies on exome sequence variant interpretation in early-onset cardiac conduction system diseases. Cardiovascular Research, 2020, 116, 2116-2130.	3.8	11
76	Clinical Diagnostic Criteria of Familial Hypercholesterolemia ― A Comparison of the Japan Atherosclerosis Society and Dutch Lipid Clinic Network Criteria ―. Circulation Journal, 2021, 85, 891-897.	1.6	11
77	Associations between questionnaires on lifestyle and atherosclerotic cardiovascular disease in a Japanese general population: A cross-sectional study. PLoS ONE, 2018, 13, e0208135.	2.5	10
78	Genomics of hypertriglyceridemia. Advances in Clinical Chemistry, 2020, 97, 141-169.	3.7	10
79	Human genetics and its impact on cardiovascular disease. Journal of Cardiology, 2022, 79, 233-239.	1.9	10
80	Asian Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia. European Cardiology Review, 2021, 16, e54.	2.2	10
81	Impact of Updated Diagnostic Criteria forÂLong QT Syndrome on Clinical Detection ofÂDiseased Patients. JACC: Clinical Electrophysiology, 2016, 2, 279-287.	3.2	9
82	Prevalence, clinical features, and prognosis of patients with extremely low high-density lipoprotein cholesterol. Journal of Clinical Lipidology, 2016, 10, 1311-1317.	1.5	9
83	A de novo mutation of the LDL receptor gene as the cause of familial hypercholesterolemia identified using whole exome sequencing. Clinica Chimica Acta, 2016, 453, 194-196.	1.1	9
84	Prehospital predictors of neurological outcomes in out-of-hospital cardiac arrest patients aged 95 years and older: A nationwide population-based observational study. Journal of Cardiology, 2017, 69, 340-344.	1.9	9
85	Effects of prehospital epinephrine administration on neurologically intact survival in bystander-witnessed out-of-hospital cardiac arrest patients with non-shockable rhythm depend on prehospital cardiopulmonary resuscitation duration required to hospital arrival. Heart and Vessels, 2018, 33, 1525-1533.	1.2	9
86	Polygenic risk scores for low-density lipoprotein cholesterol and familial hypercholesterolemia. Journal of Human Genetics, 2021, 66, 1079-1087.	2.3	9
87	Sitosterolemia Exhibiting Severe Hypercholesterolemia with Tendon Xanthomas Due to Compound Heterozygous <i>ABCG5</i> Gene Mutations Treated with Ezetimibe and Alirocumab. Internal Medicine, 2020, 59, 3033-3037.	0.7	9
88	Renal glucosuria is not associated with atherosclerotic cardiovascular disease outcome in a general Japanese community. Atherosclerosis, 2017, 261, 111-116.	0.8	8
89	Age-Specific Differences in the Duration of Prehospital Cardiopulmonary Resuscitation Administered by Emergency Medical Service Providers Necessary to Achieve Favorable Neurological Outcome After Out-of-Hospital Cardiac Arrest. Circulation Journal, 2017, 81, 652-659.	1.6	8
90	Post-prandial Remnant Lipoprotein Metabolism in Sitosterolemia. Journal of Atherosclerosis and Thrombosis, 2018, 25, 1188-1195.	2.0	8

#	Article	IF	CITATIONS
91	A Healthy Family of Familial Hypobetalipoproteinemia Caused by a Protein-truncating Variant in the PCSK9 Gene. Internal Medicine, 2020, 59, 783-787.	0.7	8
92	Serum sitosterol level predicting ABCG5 or ABCG8 genetic mutations. Clinica Chimica Acta, 2020, 507, 11-16.	1.1	8
93	Challenges of Precision Medicine for Atherosclerotic Cardiovascular Disease Based on Human Genome Information. Journal of Atherosclerosis and Thrombosis, 2021, 28, 305-313.	2.0	8
94	Effects of Different Types of Pathogenic Variants on Phenotypes of Familial Hypercholesterolemia. Frontiers in Genetics, 2022, 13, 872056.	2.3	8
95	Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three-drug lipid-lowering combination therapy. Lipids in Health and Disease, 2016, 15, 66.	3.0	7
96	Oral Fat Tolerance Test for Sitosterolemia and Familial Hypercholesterolemia: A Study Protocol. Journal of Atherosclerosis and Thrombosis, 2018, 25, 741-746.	2.0	7
97	Association of proteinuria with incident atrial fibrillation in the general Japanese population. Journal of Cardiology, 2021, 77, 100-105.	1.9	7
98	Genetic Analysis of Japanese Children Clinically Diagnosed with Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2022, 29, 667-677.	2.0	7
99	Association between Cardiovascular Health and Incident Atrial Fibrillation in the General Japanese Population Aged ≥40 Years. Nutrients, 2021, 13, 3201.	4.1	6
100	Prospective Registry Study of Primary Dyslipidemia (PROLIPID): Rationale and Study Design. Journal of Atherosclerosis and Thrombosis, 2022, 29, 953-969.	2.0	6
101	Genetic mutations, regression of Achilles tendon thickness, and cardiovascular events among patients with familial hypercholesterolemia. Atherosclerosis, 2022, 340, 28-34.	0.8	6
102	The Effect of Diet on Cardiovascular Disease, Heart Disease, and Blood Vessels. Nutrients, 2022, 14, 246.	4.1	6
103	Clinical and genetic features of sitosterolemia in Japan. Clinica Chimica Acta, 2022, 530, 39-44.	1.1	6
104	Lipoprotein metabolism in familial hypercholesterolemia: Serial assessment using a one-step ultracentrifugation method. Practical Laboratory Medicine, 2015, 1, 22-27.	1.3	5
105	Detailed analysis of lipolytic enzymes in a Japanese woman of familial lipoprotein lipase deficiency – Effects of pemafibrate treatment. Clinica Chimica Acta, 2020, 510, 216-219.	1.1	5
106	Premature Acute Myocardial Infarction in a Young Patient With Sitosterolemia. CJC Open, 2021, 3, 1085-1088.	1.5	5
107	Impact of sinus rhythm maintenance on major adverse cardiac and cerebrovascular events after catheter ablation of atrial fibrillation: insights from AF frontier ablation registry. Heart and Vessels, 2022, 37, 327-336.	1.2	5
108	Clinical whole exome sequencing in severe hypertriglyceridemia. Clinica Chimica Acta, 2019, 488, 31-39.	1.1	4

#	Article	IF	CITATIONS
109	What is the mechanism of genetic contributions to the development of atherosclerosis?. Atherosclerosis, 2020, 307, 72-74.	0.8	4
110	First-degree atrioventricular block is significantly associated with incident atrial fibrillation in the population predominantly including participants aged ≥ 60Âyears. Heart and Vessels, 2021, 36, 1401	l- 1 ² 09.	4
111	Acute Coronary Syndrome Developed in a 17-year-old Boy with Sitosterolemia Comorbid with Takayasu Arteritis: A Rare Case Report and Review of the Literature. Internal Medicine, 2022, 61, 1169-1177.	0.7	4
112	Individualized Treatment for Patients With Familial Hypercholesterolemia. Journal of Lipid and Atherosclerosis, 2022, 11, 39.	3.5	4
113	Whole Exome Sequencing in Monogenic Dyslipidemias. Journal of Atherosclerosis and Thrombosis, 2015, 22, 881-885.	2.0	3
114	A case with familial hypercholesterolemia complicated with severe systemic atherosclerosis intensively treated for more than 30 years. Journal of Cardiology Cases, 2020, 22, 216-220.	0.5	3
115	A reassessment of the Japanese clinical diagnostic criteria of familial hypercholesterolemia in a hospital-based cohort using comprehensive genetic analysis. Practical Laboratory Medicine, 2020, 22, e00180.	1.3	3
116	Hokuriku-plus familial hypercholesterolaemia registry study: rationale and study design. BMJ Open, 2020, 10, e038623.	1.9	3
117	Lipoprotein (a) and the Risk of Chronic Kidney Disease in Hospitalized Japanese Patients. Internal Medicine, 2020, 59, 1705-1710.	0.7	3
118	A teenager boy with a novel variant of Sitosterolemia presented with pancytopenia. Clinica Chimica Acta, 2022, 529, 61-66.	1.1	3
119	Prevalence, self-awareness, and LDL cholesterol levels among patients highly suspected as familial hypercholesterolemia in a Japanese community. Practical Laboratory Medicine, 2020, 22, e00181.	1.3	2
120	Severe calcification of the Achilles' tendon. European Heart Journal, 2021, 42, 2217-2217.	2.2	2
121	Huge Apertures in the Aortic Valve Due to Libman-Sachs Endocarditis. Internal Medicine, 2009, 48, 859-859.	0.7	1
122	Research update for articles published in EJCI in 2012. European Journal of Clinical Investigation, 2014, 44, 1010-1023.	3.4	1
123	Acute myocardial infarction in a patient positive for lupus anticoagulant: a case report. BMC Cardiovascular Disorders, 2019, 19, 167.	1.7	1
124	A Japanese case of familial hypercholesterolemia with a novel mutation in the <i>LDLR</i> gene. Clinical Pediatric Endocrinology, 2019, 28, 19-22.	0.8	1
125	Prevalence and Impact of Apolipoprotein E7 on LDL Cholesterol Among Patients With Familial Hypercholesterolemia. Frontiers in Cardiovascular Medicine, 2021, 8, 625852.	2.4	1
126	Do We Expect Any Pleiotropic Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition for Reducing Cardiovascular Events Beyond Low-Density Lipoprotein Cholesterol Reduction?. Circulation Journal, 2017, 81, 1098-1099.	1.6	1

#	Article	IF	CITATIONS
127	Explainable Machine Learning for Atrial Fibrillation in the General Population Using a Generalized Additive Model ― A Cross-Sectional Study ―. Circulation Reports, 2022, 4, 73-82.	1.0	1
128	Effects of artificial intelligence-SsupporTed Automated NutRiTional Intervention on LDL cholesterol Control in Patients with Familial Hypercholesterolaemia (iSTART-FH): protocol for a randomised controlled trial. BMJ Open, 2021, 11, e053453.	1.9	1
129	Children with Severe Hypercholesterolemia Caused by a Pathogenic Mutation in & lt;i>ABCG5. Internal Medicine, 2023, 62, 251-259.	0.7	1
130	Significance of Genetic Diagnosis of Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2016, 23, 554-556.	2.0	0
131	Huge right ventricular mass lesion associated with genital malignant tumor: a case report. Journal of Medical Case Reports, 2017, 11, 282.	0.8	0
132	Encouragement of Super-aggressive LDL-lowering Therapies. Journal of Coronary Artery Disease, 2019, 25, 84-89.	0.3	0
133	Polygenic Risk Scores for AtheroscleroticÂCardiovascular Disease inÂthe Asia-PacificÂRegion. JACC Asia, 2021, 1, 294-302.	1.5	0